Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate

References

• National Institute of Mental Health. Schizophrenia. National Institute of Mental Health Web site, 2014. Available at: http://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml [Last accessed 27 July 2016]
   Google Scholar
• Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-9
   PubMed Web of Science ®Google Scholar
• Feldman R, Bailey RA, Muller J, et al. Cost of schizophrenia in the Medicare program. Popul Health Manag 2014;17:190-6
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010;10:2
   PubMed Web of Science ®Google Scholar
• Olivares JM, Sermon J, Hemels M, Schreiner A. Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. Ann Gen Psychiatry 2013;12:32
   PubMed Web of Science ®Google Scholar
• Hendrie HC, Tu W, Tabbey R, et al. Health outcomes and cost of care among older adults with schizophrenia: a 10-year study using medical records across the continuum of care. Am J Geriatr Psychiatry 2014;22:427-36
   PubMed Web of Science ®Google Scholar
• Lambert TJ, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. Med J Aust 2003;178(Suppl):S67-S70
   Google Scholar
• Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005;150:1115-21
   PubMed Web of Science ®Google Scholar
• Piette JD, Heisler M, Ganoczy D, et al. Differential medication adherence among patients with schizophrenia and comorbid diabetes and hypertension. Psychiatr Serv 2007;58:207-12
   PubMed Web of Science ®Google Scholar
• Farley JF, Hansen RA, Yu-Isenberg KS, Maciejewski ML. Antipsychotic adherence and its correlation to health outcomes for chronic comorbid conditions. Prim Care Companion CNS Disord 2012;14. pii: PCC.11m01324. doi: 10.4088/PCC.11m01324. Epub 2012 Jun 21
   PubMedGoogle Scholar
• Bajor LA, Gunzler D, Einstadter D, et al. Associations between comorbid anxiety, diabetes control, and overall medical burden in patients with serious mental illness and diabetes. Int J Psychiatry Med 2015;49:309-20
   PubMed Web of Science ®Google Scholar
• Patel MX, Taylor M, David AS. Antipsychotic long-acting injections: mind the gap. Br J Psychiatry Suppl 2009;52:S1-S4
   PubMedGoogle Scholar
• Pinikahana J, Happell B, Taylor M, Keks NA. Exploring the complexity of compliance in schizophrenia. Issues Ment Health Nurs 2002;23:513-28
   PubMedGoogle Scholar
• Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 2008;8:32
   PubMed Web of Science ®Google Scholar
• Novick D, Haro JM, Suarez D, et al. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 2010;176:109-13
   PubMed Web of Science ®Google Scholar
• Brissos S, Veguilla MR, Taylor D, Balanza-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Therap Adv Psychopharmacol 2014;4:198-219
   PubMedGoogle Scholar
• Young JL, Spitz RT, Hillbrand M, Daneri G. Medication adherence failure in schizophrenia: a forensic review of rates, reasons, treatments, and prospects. J Am Acad Psychiatry Law 1999;27:426-44
   PubMed Web of Science ®Google Scholar
• Young JL, Zonana HV, Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 1986;14:105-22
   PubMedGoogle Scholar
• Risperdal Consta (risperidone) long-acting injection [package insert]. Titusville, NJ, USA: Janssen Pharmaceuticals Inc., March 2016
   Google Scholar
• Invega Sustenna (paliperidone palmitate) extended-release injectable suspension, for intramuscular use [package insert]. Titusville, NJ, USA: Janssen Pharmaceuticals Inc., March 2016
   Google Scholar
• Abilify Maintena (aripiprazole) for extended-release injectable suspension, for intramuscular use [package insert]. Rockville, MD, USA: Otsuka America Pharmaceutical Inc., January 2016
   Google Scholar
• Zyprexa Relprevv (olanzapine) for extended release injectable suspension [package insert]. Indianapolis, IN, USA: Lilly USA LLC, 2015
   Google Scholar
• Aristada (aripiprazole lauroxil) extended-release injectable suspension, for intramuscular use. Waltham, MA, USA: Alkermes Inc., May 2016.
   Google Scholar
• Diaz E, Neuse E, Sullivan MC, et al. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 2004;65:354-60
   PubMed Web of Science ®Google Scholar
• Medic G, Higashi K, Littlewood KJ, et al. Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis. Neuropsychiatr Dis Treat 2013;9:119-31
   PubMed Web of Science ®Google Scholar
• Pfeiffer PN, Ganoczy D, Valenstein M. Dosing frequency and adherence to antipsychotic medications. Psychiatr Serv 2008;59:1207-10
   PubMed Web of Science ®Google Scholar
• Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med 2011;105:435-41
   PubMed Web of Science ®Google Scholar
• Samtani MN, Sheehan JJ, Fu DJ, et al. Management of antipsychotic treatment discontinuation and interruptions using model-based simulations. Clin Pharmacol 2012;4:25-40
   PubMedGoogle Scholar
• Citrome L. Paliperidone palmitate – review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract 2010;64:216-39
   PubMed Web of Science ®Google Scholar
• Einarson TR, Maia-Lopes S, Goswami P, et al. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal. J Med Econ 2016;13:1-9. [Epub ahead of print]
   Google Scholar
• Druais S, Doutriaux A, Cognet M, et al. Cost effectiveness of paliperidone long-acting injectable versus other antipsychotics for the maintenance treatment of schizophrenia in France. Pharmacoeconomics 2016;34:363-91
   PubMed Web of Science ®Google Scholar
• Einarson TR, Pudas H, Zilbershtein R, et al. Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland. J Med Econ 2013;16:1096-105
   PubMedGoogle Scholar
• Einarson TR, Zilbershtein R, Skoupa J, et al. Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic. J Med Econ 2013;16:1089-95
   PubMedGoogle Scholar
• Marcus SC, Zummo J, Pettit AR, et al. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm 2015;21:754-68
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Campagna EJ, Muser E, Parks J, Morrato EH. Methodological considerations in estimating adherence and persistence for a long-acting injectable medication. J Manag Care Spec Pharm 2014;20:756-66
   PubMed Web of Science ®Google Scholar
• Samtani MN, Gopal S, Gassmann-Mayer C, et al. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. CNS Drugs 2011;25:829-45
   PubMed Web of Science ®Google Scholar
• Dilla T, Ciudad A, Alvarez M. Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia. Patient Prefer Adherence 2013;7:275-84
   PubMed Web of Science ®Google Scholar
• Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-9
   PubMed Web of Science ®Google Scholar
• Olivares JM, Rodriguez-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24:287-96
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries DE, et al. Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia. BMC Res Notes 2009;2:6
   PubMedGoogle Scholar
• Achilla E, McCrone P. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations. Appl Health Econ Health Policy 2013;11:95-106
   PubMedGoogle Scholar
• Baser O, Xie L, Pesa J, Durkin M. Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics. J Med Econ 2015;18:357-65
   PubMed Web of Science ®Google Scholar
• Carswell C, Wheeler A, Vanderpyl J, Robinson E. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis. Clin Drug Invest 2010;30:777-87
   PubMed Web of Science ®Google Scholar
• Crivera C, Desouza C, Kozma CM, et al. Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE). BMC Psychiatry 2011;11:168
   PubMed Web of Science ®Google Scholar
• Fuller M, Shermock K, Russo P, et al. Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. J Med Econ 2009;12:317-24
   PubMedGoogle Scholar
• Mehnert A, Nicholl D, Pudas H, et al. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. J Med Econ 2012;15:844-61
   PubMedGoogle Scholar